Osi 906

The IGF-1R inhibitors PQ401 (2768, Tocris Bioscience, Ellisville, MO, USA), OSI-906 (07333, LKT Laboratories, St. Paul, MN, USA), NVP-ADW742 (S1088, Selleck Chemicals, Houston, TX, USA), the Aurora B inhibitor ZM447439 (JS Research Chemicals Trading, Wedel, Germany), the PLK1 inhibitor BI12536 (A10134, AdooQ Bioscience, Irvine, CA, USA), and the MPS1 inhibitor AZ3146 (A11170, AdooQ Bioscience) were used. For cell-cycle synchronization to M phase, the reversible CDK1 inhibitor RO-3306 (S7747, Selleck Chemicals) was used. These inhibitors were dissolved in DMSO (Nacalai Tesque, Kyoto, Japan). Recombinant human IGF1 was purchased from Peprotech (100-11, London, UK).

The IGF-1R inhibitor OSI-906 (07333, LKT Laboratories, St. Paul, MN, USA), the Aurora B inhibitor ZM447439 (JS Research Chemicals Trading, Wedel, Germany), the proteasome inhibitor MG132 (3175-v, Peptide Institute, Osaka, Japan), the Eg5 inhibitor STLC (164739, MilliporeSigma, Burlington, MA, USA), and the microtubule-targeting agent paclitaxel (169-18611, FujiFilm Wako, Osaka, Japan) were used in this study. The CDK1 inhibitor RO-3306 (S7747, Selleck Chemicals) was used for synchronization to M phase [48 (link)]. Dimethyl sulfoxide (Nacalai Tesque, Kyoto, Japan) was used to dissolve these chemicals.